<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">33260979</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2077-0383</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>9</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical medicine</Title>
          <ISOAbbreviation>J Clin Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evans' Syndrome: From Diagnosis to Treatment.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">3851</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm9123851</ELocationID>
        <Abstract>
          <AbstractText>Evans' syndrome (ES) is defined as the concomitant or sequential association of warm auto-immune haemolytic anaemia (AIHA) with immune thrombocytopenia (ITP), and less frequently autoimmune neutropenia. ES is a rare situation that represents up to 7% of AIHA and around 2% of ITP. When AIHA and ITP occurred concomitantly, the diagnosis procedure must rule out differential diagnoses such as thrombotic microangiopathies, anaemia due to bleedings complicating ITP, vitamin deficiencies, myelodysplastic syndromes, paroxysmal nocturnal haemoglobinuria, or specific conditions like HELLP when occurring during pregnancy. As for isolated auto-immune cytopenia (AIC), the determination of the primary or secondary nature of ES is important. Indeed, the association of ES with other diseases such as haematological malignancies, systemic lupus erythematosus, infections, or primary immune deficiencies can interfere with its management or alter its prognosis. Due to the rarity of the disease, the treatment of ES is mostly extrapolated from what is recommended for isolated AIC and mostly relies on corticosteroids, rituximab, splenectomy, and supportive therapies. The place for thrombopoietin receptor agonists, erythropoietin, immunosuppressants, haematopoietic cell transplantation, and thromboprophylaxis is also discussed in this review. Despite continuous progress in the management of AIC and a gradual increase in ES survival, the mortality due to ES remains higher than the ones of isolated AIC, supporting the need for an improvement in ES management.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Audia</LastName>
            <ForeName>Sylvain</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-1772-1392</Identifier>
            <AffiliationInfo>
              <Affiliation>Service de Médecine Interne et Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalo-Universitaire Dijon Bourgogne, Université de Bourgogne Franche Comté, 21000 Dijon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grienay</LastName>
            <ForeName>Natacha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Service de Médecine Interne et Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalo-Universitaire Dijon Bourgogne, Université de Bourgogne Franche Comté, 21000 Dijon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mounier</LastName>
            <ForeName>Morgane</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Registre des Hémopathies Malignes de Côte d'Or, Centre Hospitalo-Universitaire Dijon Bourgogne, Université de Bourgogne Franche Comté, UMR 1231 Dijon, 21000 Dijon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Michel</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Service de Médecine Interne 1, Centre de Référence des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalo-Universitaire Henri Mondor, 94000 Créteil, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bonnotte</LastName>
            <ForeName>Bernard</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Service de Médecine Interne et Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalo-Universitaire Dijon Bourgogne, Université de Bourgogne Franche Comté, 21000 Dijon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Med</MedlineTA>
        <NlmUniqueID>101606588</NlmUniqueID>
        <ISSNLinking>2077-0383</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Evans’ syndrome</Keyword>
        <Keyword MajorTopicYN="N">autoimmune haemolytic anaemia</Keyword>
        <Keyword MajorTopicYN="N">immune thrombocytopenia</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>2</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33260979</ArticleId>
        <ArticleId IdType="pmc">PMC7759819</ArticleId>
        <ArticleId IdType="doi">10.3390/jcm9123851</ArticleId>
        <ArticleId IdType="pii">jcm9123851</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Evans R.S., Takahashi K., Duane R.T., Payne R., Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch. Intern. Med. 1951;87:48–65. doi: 10.1001/archinte.1951.03810010058005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.1951.03810010058005</ArticleId>
            <ArticleId IdType="pubmed">14782741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moncharmont P., Troncy J., Rigal D. IgA anti-red blood cell auto-antibodies in Evans syndrome. Hematology. 2007;12:587–589. doi: 10.1080/10245330701521481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10245330701521481</ArticleId>
            <ArticleId IdType="pubmed">17852438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel M., Chanet V., Dechartres A., Morin A.S., Piette J.C., Cirasino L., Emilia G., Zaja F., Ruggeri M., Andres E., et al.  The spectrum of Evans syndrome in adults: New insight into the disease based on the analysis of 68 cases. Blood. 2009;114:3167–3172. doi: 10.1182/blood-2009-04-215368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-04-215368</ArticleId>
            <ArticleId IdType="pubmed">19638626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen D.L., Moller S., Andersen K., Gaist D., Frederiksen H. Evans syndrome in adults—Incidence, prevalence, and survival in a nationwide cohort. Am. J. Hematol. 2019;94:1081–1090. doi: 10.1002/ajh.25574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.25574</ArticleId>
            <ArticleId IdType="pubmed">31292991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel M. Warm autoimmune hemolytic anemias and Evans syndrome in adults. Rev. Med. Interne. 2008;29:105–114. doi: 10.1016/j.revmed.2007.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.revmed.2007.08.014</ArticleId>
            <ArticleId IdType="pubmed">17980462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellini W., Fattizzo B., Zaninoni A., Radice T., Nichele I., Di Bona E., Lunghi M., Tassinari C., Alfinito F., Ferrari A., et al.  Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: A GIMEMA study of 308 patients. Blood. 2014;124:2930–2936. doi: 10.1182/blood-2014-06-583021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-06-583021</ArticleId>
            <ArticleId IdType="pubmed">25232059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jager U., Barcellini W., Broome C.M., Gertz M.A., Hill A., Hill Q.A., Jilma B., Kuter D.J., Michel M., Montillo M., et al.  Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2019 doi: 10.1016/j.blre.2019.100648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.blre.2019.100648</ArticleId>
            <ArticleId IdType="pubmed">31839434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Provan D., Arnold D.M., Bussel J.B., Chong B.H., Cooper N., Gernsheimer T., Ghanima W., Godeau B., Gonzalez-Lopez T.J., Grainger J., et al.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780–3817. doi: 10.1182/bloodadvances.2019000812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2019000812</ArticleId>
            <ArticleId IdType="pmc">PMC6880896</ArticleId>
            <ArticleId IdType="pubmed">31770441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porcelijn L., Huiskes E., Oldert G., Schipperus M., Zwaginga J.J., de Haas M. Detection of platelet autoantibodies to identify immune thrombocytopenia: State of the art. Br. J. Haematol. 2018;182:423–426. doi: 10.1111/bjh.15404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.15404</ArticleId>
            <ArticleId IdType="pubmed">29808904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger P.E. Autoimmune and other acquired neutropenias. Hematol. Am. Soc. Hematol. Educ. Program. 2016;2016:38–42. doi: 10.1182/asheducation-2016.1.38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/asheducation-2016.1.38</ArticleId>
            <ArticleId IdType="pmc">PMC5380382</ArticleId>
            <ArticleId IdType="pubmed">27913460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucas G., Rogers S., de Haas M., Porcelijn L., Bux J. Report on the Fourth International Granulocyte Immunology Workshop: Progress toward quality assessment. Transfusion. 2002;42:462–468. doi: 10.1046/j.1525-1438.2002.00053.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1525-1438.2002.00053.x</ArticleId>
            <ArticleId IdType="pubmed">12076294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youinou P., Jamin C., Le Pottier L., Renaudineau Y., Hillion S., Pers J.O. Diagnostic criteria for autoimmune neutropenia. Autoimmun. Rev. 2014;13:574–576. doi: 10.1016/j.autrev.2014.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2014.01.001</ArticleId>
            <ArticleId IdType="pubmed">24418296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidel M.G. Autoimmune and other cytopenias in primary immunodeficiencies: Pathomechanisms, novel differential diagnoses, and treatment. Blood. 2014;124:2337–2344. doi: 10.1182/blood-2014-06-583260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-06-583260</ArticleId>
            <ArticleId IdType="pmc">PMC4192747</ArticleId>
            <ArticleId IdType="pubmed">25163701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fattizzo B., Barcellini W. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects. Front. Oncol. 2019;9:1435. doi: 10.3389/fonc.2019.01435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.01435</ArticleId>
            <ArticleId IdType="pmc">PMC6967408</ArticleId>
            <ArticleId IdType="pubmed">31998632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carli G., Visco C., Falisi E., Perbellini O., Novella E., Giaretta I., Ferrarini I., Sandini A., Alghisi A., Ambrosetti A., et al.  Evans syndrome secondary to chronic lymphocytic leukaemia: Presentation, treatment, and outcome. Ann. Hematol. 2016;95:863–870. doi: 10.1007/s00277-016-2642-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00277-016-2642-x</ArticleId>
            <ArticleId IdType="pubmed">27001309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Wu X., Wang L., Li J., Chen H., Zhao Y., Zheng W. Clinical Features of Systemic Lupus Erythematosus Patients Complicated With Evans Syndrome: A Case-Control, Single Center Study. Medicine. 2016;95:e3279. doi: 10.1097/MD.0000000000003279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000003279</ArticleId>
            <ArticleId IdType="pmc">PMC4839809</ArticleId>
            <ArticleId IdType="pubmed">27082565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costallat G.L., Appenzeller S., Costallat L.T. Evans syndrome and systemic lupus erythematosus: Clinical presentation and outcome. Jt. Bone Spine. 2012;79:362–364. doi: 10.1016/j.jbspin.2011.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbspin.2011.07.004</ArticleId>
            <ArticleId IdType="pubmed">21944976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M., Nguyen C.B., Yeung Z., Sanchez K., Rosen D., Bushan S. Evans syndrome in a patient with COVID-19. Br. J. Haematol. 2020;190:e59–e61. doi: 10.1111/bjh.16846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.16846</ArticleId>
            <ArticleId IdType="pmc">PMC7276874</ArticleId>
            <ArticleId IdType="pubmed">32420629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotz S.J., Ware R.E., Kumar A. Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatr. Blood Cancer. 2018;65:e27260. doi: 10.1002/pbc.27260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.27260</ArticleId>
            <ArticleId IdType="pubmed">29856527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefkou E., Nelson-Piercy C., Hunt B.J. Evans’ syndrome in pregnancy: A systematic literature review and two new cases. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010;149:10–17. doi: 10.1016/j.ejogrb.2009.11.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejogrb.2009.11.022</ArticleId>
            <ArticleId IdType="pubmed">20031296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scully M. Thrombocytopenia in hospitalized patients: Approach to the patient with thrombotic microangiopathy. Hematol. Am. Soc. Hematol. Educ. Program. 2017;2017:651–659. doi: 10.1182/asheducation-2017.1.651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/asheducation-2017.1.651</ArticleId>
            <ArticleId IdType="pmc">PMC6142615</ArticleId>
            <ArticleId IdType="pubmed">29222317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grall M., Azoulay E., Galicier L., Provot F., Wynckel A., Poullin P., Grange S., Halimi J.M., Lautrette A., Delmas Y., et al.  Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. Am. J. Hematol. 2017;92:381–387. doi: 10.1002/ajh.24665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.24665</ArticleId>
            <ArticleId IdType="pubmed">28133771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andres E., Affenberger S., Zimmer J., Vinzio S., Grosu D., Pistol G., Maloisel F., Weitten T., Kaltenbach G., Blickle J.F. Current hematological findings in cobalamin deficiency. A study of 201 consecutive patients with documented cobalamin deficiency. Clin. Lab. Haematol. 2006;28:50–56. doi: 10.1111/j.1365-2257.2006.00755.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2257.2006.00755.x</ArticleId>
            <ArticleId IdType="pubmed">16430460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., Bloomfield C.D., Cazzola M., Vardiman J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi: 10.1182/blood-2016-03-643544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2016-03-643544</ArticleId>
            <ArticleId IdType="pubmed">27069254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodsky R.A. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804–2811. doi: 10.1182/blood-2014-02-522128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-02-522128</ArticleId>
            <ArticleId IdType="pmc">PMC4215311</ArticleId>
            <ArticleId IdType="pubmed">25237200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neunert C., Terrell D.R., Arnold D.M., Buchanan G., Cines D.B., Cooper N., Cuker A., Despotovic J.M., George J.N., Grace R.F., et al.  American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829–3866. doi: 10.1182/bloodadvances.2019000966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2019000966</ArticleId>
            <ArticleId IdType="pmc">PMC6963252</ArticleId>
            <ArticleId IdType="pubmed">31794604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y., Ji X.B., Wang Y.W., Wang J.X., Yang E.Q., Wang Z.C., Sang Y.Q., Bi Z.M., Ren C.A., Zhou F., et al.  High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial. Blood. 2016;127:296–302. doi: 10.1182/blood-2015-07-659656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2015-07-659656</ArticleId>
            <ArticleId IdType="pubmed">26480931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mithoowani S., Gregory-Miller K., Goy J., Miller M.C., Wang G., Noroozi N., Kelton J.G., Arnold D.M. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: A systematic review and meta-analysis. Lancet Haematol. 2016;3:e489–e496. doi: 10.1016/S2352-3026(16)30109-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2352-3026(16)30109-0</ArticleId>
            <ArticleId IdType="pubmed">27658982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flores G., Cunningham-Rundles C., Newland A.C., Bussel J.B. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients. Am. J. Hematol. 1993;44:237–242. doi: 10.1002/ajh.2830440404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.2830440404</ArticleId>
            <ArticleId IdType="pubmed">8237993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godeau B., Chevret S., Varet B., Lefrere F., Zini J.M., Bassompierre F., Cheze S., Legouffe E., Hulin C., Grange M.J., et al.  Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial. Lancet. 2002;359:23–29. doi: 10.1016/S0140-6736(02)07275-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(02)07275-6</ArticleId>
            <ArticleId IdType="pubmed">11809183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birgens H., Frederiksen H., Hasselbalch H.C., Rasmussen I.H., Nielsen O.J., Kjeldsen L., Larsen H., Mourits-Andersen T., Plesner T., Ronnov-Jessen D., et al.  A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br. J. Haematol. 2013;163:393–399. doi: 10.1111/bjh.12541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.12541</ArticleId>
            <ArticleId IdType="pubmed">23981017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel M., Terriou L., Roudot-Thoraval F., Hamidou M., Ebbo M., Le Guenno G., Galicier L., Audia S., Royer B., Sophie Morin A., et al.  A Randomized and Double-Blind Controlled Trial Evaluating the Safety and Efficacy of Rituximab for Warm Auto-Immune Hemolytic Anemia in Adults (the RAIHA study) Am. J. Hematol. 2016 doi: 10.1002/ajh.24570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.24570</ArticleId>
            <ArticleId IdType="pubmed">27696475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshayes S., Khellaf M., Zarour A., Layese R., Fain O., Terriou L., Viallard J.F., Cheze S., Graveleau J., Slama B., et al.  Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. Am. J. Hematol. 2019;94:1314–1324. doi: 10.1002/ajh.25632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.25632</ArticleId>
            <ArticleId IdType="pubmed">31489694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aladjidi N., Fernandes H., Leblanc T., Vareliette A., Rieux-Laucat F., Bertrand Y., Chambost H., Pasquet M., Mazingue F., Guitton C., et al.  Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort. Front. Pediatr. 2015;3:79. doi: 10.3389/fped.2015.00079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2015.00079</ArticleId>
            <ArticleId IdType="pmc">PMC4586429</ArticleId>
            <ArticleId IdType="pubmed">26484337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bader-Meunier B., Aladjidi N., Bellmann F., Monpoux F., Nelken B., Robert A., Armari-Alla C., Picard C., Ledeist F., Munzer M., et al.  Rituximab therapy for childhood Evans syndrome. Haematologica. 2007;92:1691–1694. doi: 10.3324/haematol.11540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.11540</ArticleId>
            <ArticleId IdType="pubmed">18055994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104:2623–2634. doi: 10.1182/blood-2004-03-1168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2004-03-1168</ArticleId>
            <ArticleId IdType="pubmed">15217831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roumier M., Loustau V., Guillaud C., Languille L., Mahevas M., Khellaf M., Limal N., Noizat-Pirenne F., Godeau B., Michel M. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am. J. Hematol. 2014;89:E150–E155. doi: 10.1002/ajh.23767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.23767</ArticleId>
            <ArticleId IdType="pubmed">24847759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quiquandon I., Fenaux P., Caulier M.T., Pagniez D., Huart J.J., Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: A report on 53 cases. Br. J. Haematol. 1990;74:223–228. doi: 10.1111/j.1365-2141.1990.tb02569.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.1990.tb02569.x</ArticleId>
            <ArticleId IdType="pubmed">2317458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pizzuto J., Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood. 1984;64:1179–1183. doi: 10.1182/blood.V64.6.1179.1179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V64.6.1179.1179</ArticleId>
            <ArticleId IdType="pubmed">6388663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choudhary D.R., Naithani R., Mahapatra M., Kumar R., Mishra P., Saxena R. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica. 2008;93:e61–e62.discussion e63. doi: 10.3324/haematol.13481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.13481</ArticleId>
            <ArticleId IdType="pubmed">18827257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kappers-Klunne M.C., van’t Veer M.B. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br. J. Haematol. 2001;114:121–125. doi: 10.1046/j.1365-2141.2001.02893.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2141.2001.02893.x</ArticleId>
            <ArticleId IdType="pubmed">11472356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miano M., Ramenghi U., Russo G., Rubert L., Barone A., Tucci F., Farruggia P., Petrone A., Mondino A., Lo Valvo L., et al.  Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br. J. Haematol. 2016;175:490–495. doi: 10.1111/bjh.14261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.14261</ArticleId>
            <ArticleId IdType="pubmed">27447678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neven B., Magerus-Chatinet A., Florkin B., Gobert D., Lambotte O., De Somer L., Lanzarotti N., Stolzenberg M.C., Bader-Meunier B., Aladjidi N., et al.  A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118:4798–4807. doi: 10.1182/blood-2011-04-347641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-04-347641</ArticleId>
            <ArticleId IdType="pubmed">21885602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor A., Neave L., Solanki S., Westwood J.P., Terrinonive I., McGuckin S., Kothari J., Cooper N., Stasi R., Scully M. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br. J. Haematol. 2015;171:625–630. doi: 10.1111/bjh.13622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.13622</ArticleId>
            <ArticleId IdType="pubmed">26250874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colovic M., Suvajdzic N., Colovic N., Tomin D., Vidovic A., Palibrk V. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets. 2011;22:153–156. doi: 10.3109/09537104.2010.520372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/09537104.2010.520372</ArticleId>
            <ArticleId IdType="pubmed">21142405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stirnemann J., Kaddouri N., Khellaf M., Morin A.S., Prendki V., Michel M., Mekinian A., Bierling P., Fenaux P., Godeau B., et al.  Vincristine efficacy and safety in treating immune thrombocytopenia: A retrospective study of 35 patients. Eur. J. Haematol. 2015 doi: 10.1111/ejh.12586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejh.12586</ArticleId>
            <ArticleId IdType="pubmed">25976731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Audia S., Godeau B., Bonnotte B. Is there still a place for “old therapies” in the management of immune thrombocytopenia? Rev. Med. Interne. 2016;37:43–49. doi: 10.1016/j.revmed.2015.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.revmed.2015.08.007</ArticleId>
            <ArticleId IdType="pubmed">26422785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruivard M., Tournilhac O., Montel S., Fouilhoux A.C., Quainon F., Lenat A., Travade P., Philippe P. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: A retrospective case-control study. J. Clin. Apher. 2006;21:202–206. doi: 10.1002/jca.20096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jca.20096</ArticleId>
            <ArticleId IdType="pubmed">16607631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Baeyer H. Plasmapheresis in immune hematology: Review of clinical outcome data with respect to evidence-based medicine and clinical experience. Ther Apher. Dial. 2003;7:127–140. doi: 10.1046/j.1526-0968.2003.00004.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1526-0968.2003.00004.x</ArticleId>
            <ArticleId IdType="pubmed">12921129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padmanabhan A., Connelly-Smith L., Aqui N., Balogun R.A., Klingel R., Meyer E., Pham H.P., Schneiderman J., Witt V., Wu Y., et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J. Clin. Apher. 2019;34:171–354. doi: 10.1002/jca.21705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jca.21705</ArticleId>
            <ArticleId IdType="pubmed">31180581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill Q.A., Stamps R., Massey E., Grainger J.D., Provan D., Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. Br. J. Haematol. 2017;176:395–411. doi: 10.1111/bjh.14478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.14478</ArticleId>
            <ArticleId IdType="pubmed">28005293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel R., Chopra S., Tobian A.A.R., Ness P.M., Frank S.M., Cushing M., Vasovic L., Kaicker S., Takemoto C., Josephson C.D., et al.  Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion. 2019;59:169–176. doi: 10.1111/trf.15069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/trf.15069</ArticleId>
            <ArticleId IdType="pubmed">30520045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spahr J.E., Rodgers G.M. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: A retrospective review of 40 patients. Am. J. Hematol. 2008;83:122–125. doi: 10.1002/ajh.21060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.21060</ArticleId>
            <ArticleId IdType="pubmed">17874448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Audia S., Bach B., Samson M., Lakomy D., Bour J.B., Burlet B., Guy J., Duvillard L., Branger M., Leguy-Seguin V., et al.  Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS ONE. 2018;13:e0207218.  doi: 10.1371/journal.pone.0207218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0207218</ArticleId>
            <ArticleId IdType="pmc">PMC6224177</ArticleId>
            <ArticleId IdType="pubmed">30408135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hendrick A.M. Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism? Hematology. 2003;8:53–56. doi: 10.1080/1024533021000059474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1024533021000059474</ArticleId>
            <ArticleId IdType="pubmed">12623428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lecouffe-Desprets M., Graveleau J., Artifoni M., Connault J., Agard C., Pottier P., Hamidou M., Neel A. Hemolytic disorders and venous thrombosis: An update. Rev. Med. Interne. 2019;40:232–237. doi: 10.1016/j.revmed.2018.10.387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.revmed.2018.10.387</ArticleId>
            <ArticleId IdType="pubmed">30773236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yusuf H.R., Hooper W.C., Grosse S.D., Parker C.S., Boulet S.L., Ortel T.L. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: A study among a U.S. cohort of commercial insurance enrollees. Thromb. Res. 2015;135:50–57. doi: 10.1016/j.thromres.2014.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2014.10.012</ArticleId>
            <ArticleId IdType="pmc">PMC4480419</ArticleId>
            <ArticleId IdType="pubmed">25456001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fattizzo B., Michel M., Zaninoni A., Giannotta J., Guillet S., Frederiksen H., Vos J.M.I., Mauro F.R., Jilma B., Patriarca A., et al.  Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: A multicentre international study. Haematologica. 2020 doi: 10.3324/haematol.2020.250522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2020.250522</ArticleId>
            <ArticleId IdType="pmc">PMC7849557</ArticleId>
            <ArticleId IdType="pubmed">32354865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bussel J.B., Cheng G., Saleh M.N., Psaila B., Kovaleva L., Meddeb B., Kloczko J., Hassani H., Mayer B., Stone N.L., et al.  Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 2007;357:2237–2247. doi: 10.1056/NEJMoa073275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa073275</ArticleId>
            <ArticleId IdType="pubmed">18046028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuter D.J., Bussel J.B., Lyons R.M., Pullarkat V., Gernsheimer T.B., Senecal F.M., Aledort L.M., George J.N., Kessler C.M., Sanz M.A., et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet. 2008;371:395–403. doi: 10.1016/S0140-6736(08)60203-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(08)60203-2</ArticleId>
            <ArticleId IdType="pubmed">18242413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Nieto J.A., Martin-Suarez I., Quattrino S., Ortiz-Lopez E., Munoz-Beamud F.R., Colchero-Fernandez J., Alcoucer-Diaz M.R. The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus. 2011;20:1321–1323. doi: 10.1177/0961203311404913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203311404913</ArticleId>
            <ArticleId IdType="pubmed">21719526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz-Arguelles G.J., Ruiz-Delgado G.J., Velazquez-Sanchez-de-Cima S., Zamora-Ortiz G. Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab. Hematology. 2013;18:175–177. doi: 10.1179/1607845412Y.0000000060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1179/1607845412Y.0000000060</ArticleId>
            <ArticleId IdType="pubmed">23321502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khellaf M., Michel M., Schaeffer A., Bierling P., Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005;90:829–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15951296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buetens O.W., Ness P.M. Red blood cell transfusion in autoimmune hemolytic anemia. Curr. Opin. Hematol. 2003;10:429–433. doi: 10.1097/00062752-200311000-00006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00062752-200311000-00006</ArticleId>
            <ArticleId IdType="pubmed">14564173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serris A., Amoura Z., Canoui-Poitrine F., Terrier B., Hachulla E., Costedoat-Chalumeau N., Papo T., Lambotte O., Saadoun D., Hie M., et al.  Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am. J. Hematol. 2018;93:424–429. doi: 10.1002/ajh.24999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.24999</ArticleId>
            <ArticleId IdType="pubmed">29247540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulpizio E.D., Raghunathan V., Shatzel J.J., Zilberman-Rudenko J., Worrest T., Sheppard B.C., DeLoughery T.G. Long-term remission rates after splenectomy in adults with Evans syndrome compared to immune thrombocytopenia: A single-center retrospective study. Eur. J. Haematol. 2020;104:55–58. doi: 10.1111/ejh.13336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejh.13336</ArticleId>
            <ArticleId IdType="pmc">PMC7023892</ArticleId>
            <ArticleId IdType="pubmed">31594025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bride K.L., Vincent T., Smith-Whitley K., Lambert M.P., Bleesing J.J., Seif A.E., Manno C.S., Casper J., Grupp S.A., Teachey D.T. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: Results of a prospective multi-institutional trial. Blood. 2016;127:17–28. doi: 10.1182/blood-2015-07-657981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2015-07-657981</ArticleId>
            <ArticleId IdType="pmc">PMC4705607</ArticleId>
            <ArticleId IdType="pubmed">26504182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellini W., Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front. Immunol. 2020;11:946. doi: 10.3389/fimmu.2020.00946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00946</ArticleId>
            <ArticleId IdType="pmc">PMC7325906</ArticleId>
            <ArticleId IdType="pubmed">32655543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Audia S., Mahevas M., Bonnotte B. Immune thrombocytopenia: From pathogenesis to treatment. Rev. Med. Interne. 2020 doi: 10.1016/j.revmed.2020.06.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.revmed.2020.06.020</ArticleId>
            <ArticleId IdType="pubmed">32741715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huhn R.D., Fogarty P.F., Nakamura R., Read E.J., Leitman S.F., Rick M.E., Kimball J., Greene A., Hansmann K., Gratwohl A., et al.  High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003;101:71–77. doi: 10.1182/blood-2001-12-0171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2001-12-0171</ArticleId>
            <ArticleId IdType="pubmed">12393623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Passweg J.R., Rabusin M. Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias. Autoimmunity. 2008;41:660–665. doi: 10.1080/08916930802198436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08916930802198436</ArticleId>
            <ArticleId IdType="pubmed">18958755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moulis G., Comont T., Adoue D. New insights into the epidemiology of immune thrombocytopenia in adult patients: Impact for clinical practice. Rev. Med. Interne. 2020 doi: 10.1016/j.revmed.2020.05.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.revmed.2020.05.018</ArticleId>
            <ArticleId IdType="pubmed">32798089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lecouffe-Desprets M., Neel A., Graveleau J., Leux C., Perrin F., Visomblain B., Artifoni M., Masseau A., Connault J., Pottier P., et al.  Venous thromboembolism related to warm autoimmune hemolytic anemia: A case-control study. Autoimmun. Rev. 2015;14:1023–1028. doi: 10.1016/j.autrev.2015.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2015.07.001</ArticleId>
            <ArticleId IdType="pubmed">26162301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel M., Ruggeri M., Gonzalez-Lopez T.J., Alkindi S.S., Cheze S., Ghanima W., Tvedt T.H.A., Ebbo M., Terriou L., Bussel J.B., et al.  Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: Results from a multicenter study. Blood. 2020 doi: 10.1182/blood.2020007594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2020007594</ArticleId>
            <ArticleId IdType="pubmed">32814348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Martinez M.U., Baranda-Candido L., Gonzalez-Amaro R., Perez-Ramirez O., Abud-Mendoza C. Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. Rheumatology (Oxford) 2013;52:405–406. doi: 10.1093/rheumatology/kes164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kes164</ArticleId>
            <ArticleId IdType="pubmed">22772325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boruchov D.M., Gururangan S., Driscoll M.C., Bussel J.B. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP) Blood. 2007;110:3526–3531. doi: 10.1182/blood-2007-01-065763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2007-01-065763</ArticleId>
            <ArticleId IdType="pubmed">17698634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roumier M., Le Burel S., Audia S., Chauchet A., Goussef M., Hamidou M., Liferman F., Moulis G., Lioger B., Galicier L., et al.  High dose Romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. Am. J. Hematol. 2020 doi: 10.1002/ajh.26040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.26040</ArticleId>
            <ArticleId IdType="pubmed">33125750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petz L.D. A physician’s guide to transfusion in autoimmune haemolytic anaemia. Br. J. Haematol. 2004;124:712–716. doi: 10.1111/j.1365-2141.2004.04841.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2004.04841.x</ArticleId>
            <ArticleId IdType="pubmed">15009058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellini W., Fattizzo B., Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev. Clin. Immunol. 2018;14:857–872. doi: 10.1080/1744666X.2018.1521722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1744666X.2018.1521722</ArticleId>
            <ArticleId IdType="pubmed">30204521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma K., Caplan S. Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy. Case Rep. Hematol. 2016;2016:9181698. doi: 10.1155/2016/9181698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/9181698</ArticleId>
            <ArticleId IdType="pmc">PMC4820603</ArticleId>
            <ArticleId IdType="pubmed">27092282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neave L., Wilson A.J., Lissack M., Scully M. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab. BMJ Case Rep. 2018;11 doi: 10.1136/bcr-2018-226429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2018-226429</ArticleId>
            <ArticleId IdType="pmc">PMC6301595</ArticleId>
            <ArticleId IdType="pubmed">30567234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannering N., Hansen D.L., Frederiksen H. Evans syndrome in children below 13 years of age—A nationwide population-based cohort study. PLoS ONE. 2020;15:e0231284.  doi: 10.1371/journal.pone.0231284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0231284</ArticleId>
            <ArticleId IdType="pmc">PMC7145102</ArticleId>
            <ArticleId IdType="pubmed">32271826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crow Y.J., Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat. Rev. Immunol. 2015;15:429–440. doi: 10.1038/nri3850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3850</ArticleId>
            <ArticleId IdType="pubmed">26052098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjadj J., Aladjidi N., Fernandes H., Leverger G., Magerus-Chatinet A., Mazerolles F., Stolzenberg M.C., Jacques S., Picard C., Rosain J., et al.  Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood. 2019;134:9–21. doi: 10.1182/blood-2018-11-887141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-11-887141</ArticleId>
            <ArticleId IdType="pubmed">30940614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabre A., Marchal S., Barlogis V., Mari B., Barbry P., Rohrlich P.S., Forbes L.R., Vogel T.P., Giovannini-Chami L. Clinical Aspects of STAT3 Gain-of-Function Germline Mutations: A Systematic Review. J. Allergy Clin. Immunol. Pract. 2019;7:1958–1969 e1959. doi: 10.1016/j.jaip.2019.02.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2019.02.018</ArticleId>
            <ArticleId IdType="pubmed">30825606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan S.E., Haapaniemi E., Russell M.A., Caswell R., Allen H.L., De Franco E., McDonald T.J., Rajala H., Ramelius A., Barton J., et al.  Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat. Genet. 2014;46:812–814. doi: 10.1038/ng.3040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3040</ArticleId>
            <ArticleId IdType="pmc">PMC4129488</ArticleId>
            <ArticleId IdType="pubmed">25038750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angulo I., Vadas O., Garçon F., Banham-Hall E., Plagnol V., Leahy T.R., Baxendale H., Coulter T., Curtis J., Wu C., et al.  Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342:866–871. doi: 10.1126/science.1243292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1243292</ArticleId>
            <ArticleId IdType="pmc">PMC3930011</ArticleId>
            <ArticleId IdType="pubmed">24136356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neven Q., Boulanger C., Bruwier A., de Ville de Goyet M., Meyts I., Moens L., Van Damme A., Brichard B. Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD) J. Clin. Immunol. 2020 doi: 10.1007/s10875-020-00883-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-020-00883-7</ArticleId>
            <ArticleId IdType="pubmed">33011939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loh M.L., Sakai D.S., Flotho C., Kang M., Fliegauf M., Archambeault S., Mullighan C.G., Chen L., Bergstraesser E., Bueso-Ramos C.E., et al.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114:1859–1863. doi: 10.1182/blood-2009-01-198416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-01-198416</ArticleId>
            <ArticleId IdType="pmc">PMC2738571</ArticleId>
            <ArticleId IdType="pubmed">19571318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farmer J.R., Foldvari Z., Ujhazi B., De Ravin S.S., Chen K., Bleesing J.J.H., Schuetz C., Al-Herz W., Abraham R.S., Joshi A.Y., et al.  Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. J. Allergy Clin. Immunol Pract. 2019;7:1970–1985 e1974. doi: 10.1016/j.jaip.2019.02.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2019.02.038</ArticleId>
            <ArticleId IdType="pmc">PMC6612449</ArticleId>
            <ArticleId IdType="pubmed">30877075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuetz C., Huck K., Gudowius S., Megahed M., Feyen O., Hubner B., Schneider D.T., Manfras B., Pannicke U., Willemze R., et al.  An immunodeficiency disease with RAG mutations and granulomas. N. Engl. J. Med. 2008;358:2030–2038. doi: 10.1056/NEJMoa073966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa073966</ArticleId>
            <ArticleId IdType="pubmed">18463379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice G.I., Kasher P.R., Forte G.M., Mannion N.M., Greenwood S.M., Szynkiewicz M., Dickerson J.E., Bhaskar S.S., Zampini M., Briggs T.A., et al.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat. Genet. 2012;44:1243–1248. doi: 10.1038/ng.2414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2414</ArticleId>
            <ArticleId IdType="pmc">PMC4154508</ArticleId>
            <ArticleId IdType="pubmed">23001123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feuille E.J., Anooshiravani N., Sullivan K.E., Fuleihan R.L., Cunningham-Rundles C. Autoimmune Cytopenias and Associated Conditions in CVID: A Report from the USIDNET Registry. J. Clin. Immunol. 2018;38:28–34. doi: 10.1007/s10875-017-0456-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-017-0456-9</ArticleId>
            <ArticleId IdType="pmc">PMC5743637</ArticleId>
            <ArticleId IdType="pubmed">29080979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel M., Chanet V., Galicier L., Ruivard M., Levy Y., Hermine O., Oksenhendler E., Schaeffer A., Bierling P., Godeau B. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: Analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004;83:254–263. doi: 10.1097/01.md.0000133624.65946.40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.md.0000133624.65946.40</ArticleId>
            <ArticleId IdType="pubmed">15232313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira J.B., Bleesing J.J., Dianzani U., Fleisher T.A., Jaffe E.S., Lenardo M.J., Rieux-Laucat F., Siegel R.M., Su H.C., Teachey D.T., et al.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop. Blood. 2010;116:e35–e40. doi: 10.1182/blood-2010-04-280347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2010-04-280347</ArticleId>
            <ArticleId IdType="pmc">PMC2953894</ArticleId>
            <ArticleId IdType="pubmed">20538792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao V.K., Oliveira J.B. How I treat autoimmune lymphoproliferative syndrome. Blood. 2011;118:5741–5751. doi: 10.1182/blood-2011-07-325217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-07-325217</ArticleId>
            <ArticleId IdType="pmc">PMC3228494</ArticleId>
            <ArticleId IdType="pubmed">21885601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Besnard C., Levy E., Aladjidi N., Stolzenberg M.C., Magerus-Chatinet A., Alibeu O., Nitschke P., Blanche S., Hermine O., Jeziorski E., et al.  Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clin. Immunol. 2018;188:52–57. doi: 10.1016/j.clim.2017.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2017.12.009</ArticleId>
            <ArticleId IdType="pubmed">29330115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun D., Heimall J. Disorders of CTLA-4 expression, how they lead to CVID and dysregulated immune responses. Curr. Opin. Allergy Clin. Immunol. 2019;19:578–585. doi: 10.1097/ACI.0000000000000590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/ACI.0000000000000590</ArticleId>
            <ArticleId IdType="pubmed">31573993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwab C., Gabrysch A., Olbrich P., Patiño V., Warnatz K., Wolff D., Hoshino A., Kobayashi M., Imai K., Takagi M., et al.  Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J. Allergy Clin. Immunol. 2018;142:1932–1946. doi: 10.1016/j.jaci.2018.02.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2018.02.055</ArticleId>
            <ArticleId IdType="pmc">PMC6215742</ArticleId>
            <ArticleId IdType="pubmed">29729943</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
